LLY / Pran, page-4

Maybe PBT2 is looking better and better. Surely, they know that the Dish results will be published soon. Surely, by now, they know that showing small improvements, or small improvements in the slow rate of decline, in cognitive function over very long periods of time is not a winning strategy. Somebody, somewhere in that company must be kicking themselves for cherry picking data and expecting a wink from the FDA.

If PBT2 were in the hands of BP, with all their insider influence at the FDA, and deep pockets ... one can only imagine - no pun intended. There wouldn't be any dog studies popping up unexpectedly. They could have PBT2 for the spare change in the plush sofas in their mahogany paneled offices.

In my opinion, the makes the publication of the Dish results 10x more powerful. Even the collective idiocy of Washington, and plush boardrooms across the world, must realize that the path to an effective AD prophylactic therapy will not come from multi-billion dollar, multi-decade clinical trials with cherry-picked data, questionable safety, and winks from the FDA.

When the Dish results go mainstream, it will beg some tough questions, questions the FDA and corporate types might have a tough time answering.